NEW YORK — Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc., recently announced its largest portfolio expansion in Australia to date. The expanded medical cannabis offering reinforces Tilray Medical’s long-term commitment to the Australian market and supports increased patient access to regulated, clinically supported medical cannabis products.
Tilray Medical has operated in Australia for several years, supplying EU‑GMP certified medical cannabis through established prescriber, pharmacy, and clinical distribution channels. This latest expansion represents a scaled increase in Tilray’s local portfolio aligned with rising demand across Australia’s regulated medical system and Tilray’s continued commitment to supply reliable and compliant medical cannabis.
Rajnish Ohri, President, International, Tilray Brands, stated, “Australia represents an important strategic market within our international growth strategy. This launch reflects our long-term commitment to delivering quality, differentiated cannabis products.”
Mr. Ohri continued, “By bringing together proven genetics, rigorous quality standards, and our strong local market expertise, we are excited to support the evolving needs of the Australian community. This milestone reflects our continued investment across priority global markets, as we broaden access to trusted cannabis products worldwide.”
Over the coming months, Tilray Medical Australia will expand its medical cannabis portfolio with the introduction of new products across multiple formats under its Redecan and Good Supply brands, further enhancing treatment options for healthcare professionals and patients. The Redecan portfolio will include medical cannabis flower, extracts, vapes, and pastilles, while Good Supply will introduce new medical cannabis flower offerings, broadening access to high-potency, patient-focused medical cannabis solutions.
Tilray Medical continues to be a leading global provider of pharmaceutical‑grade medical cannabis, supplying regulated medical markets across Europe, North America, and Australia. Through ongoing investment in education, product stewardship, and compliant supply pathways, Tilray Medical remains focused on supporting safe, consistent access for patients worldwide. —GlobeNewswire
